drugset
drugset / Trial / NCT03639883

A Safety and Efficacy Study to Evaluate AIV001 in Wound Healing Following Surgical Incision

NCT03639883 ↗

Phase 1/2 Completed 16 enrolled AiViva BioPharma, Inc.
RandomizedSequentialTriple-blindTreatment

Summary

To evaluate the safety, efficacy and pharmacokinetic profile of ascending concentrations of the study medication compared with vehicle in subjects with incisional wounds

Timeline

Start
2018-11-05
Primary completion
2019-12-04
Completion
2019-12-19

Drugs

EvaluationDrugModalityDoseRoute
Subject AIV001 Unknown 0.033 % Other
Subject AIV001 Unknown 0.1 % Other
Subject AIV001 Unknown 0.3 % Other
Subject AIV001 Unknown 1 % Other

Indications

No indication recorded.